Snowden Capital Advisors LLC Viking Therapeutics, Inc. Transaction History
Snowden Capital Advisors LLC
- $3.29 Billion
- Q3 2024
A detailed history of Snowden Capital Advisors LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Snowden Capital Advisors LLC holds 4,543 shares of VKTX stock, worth $133,973. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,543Holding current value
$133,973% of portfolio
0.01%Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
472Shares Held
66.2MCall Options Held
5.95MPut Options Held
3.43M-
Vanguard Group Inc Valley Forge, PA10.2MShares$300 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$178 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$138 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$63.6 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$55.5 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.26B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...